Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses

Expert Opinion on Investigational Drugs

Volumn 20, Issue 2, 2011, Pages 239-254

  Narayanan, Aarthi ^a   Bailey, Charles ^a   Kashanchi, Fatah ^a   Kehn Hall, Kylene ^a  

^a GEORGE MASON UNIVERSITY   (United States)

Author keywords

hemorrhagic fever viruses; host response based inhibitors; influenza; inhibitors; pathogen based inhibitors; smallpox

Indexed keywords

1 (4,5 DIHYDROXY 3 HYDROXYMETHYL 2 CYCLOPENTEN 1 YL)CYTOSINE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; ACETYLSALICYLIC ACID; AMANTADINE; ANTIVIRUS AGENT; CANERTINIB; CARBODINE; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; CYCLOPENTYL CYTOSINE; FAVIPIRAVIR; HEMAGGLUTININ; IMATINIB; MESSENGER RNA; METISAZONE; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 9F4; NONSTRUCTURAL PROTEIN 1; OROTIDINE 5' PHOSPHATE DECARBOXYLASE; OSELTAMIVIR; PERAMIVIR; PIRAZOFURIN; RIBAVIRIN; RIFAMPICIN; RIMANTADINE; S ADENOSYLHOMOCYSTEINE; TARIBAVIRIN; TECOVIRIMAT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIDARABINE; VIRUS DNA; VIRUS SIALIDASE; ZANAMIVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARENAVIRUS; ARGENTINE HEMORRHAGIC FEVER; BIOLOGICAL WARFARE; BOLIVIAN HEMORRHAGIC FEVER; BUNYAVIRUS; CRIMEAN CONGO HEMORRHAGIC FEVER; DISEASE CARRIER; DRUG APPROVAL; DRUG EFFICACY; HANTAVIRUS; HEMORRHAGIC FEVER; HIGH THROUGHPUT SCREENING; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; KIDNEY FAILURE; LASSA FEVER; MARBURG VIRUS; NONHUMAN; PRESCRIPTION; RETINITIS; REVIEW; RIFT VALLEY FEVER; RNA SYNTHESIS; SMALLPOX; SMALLPOX VIRUS; VENEZUELAN HEMORRHAGIC FEVER; VIRION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; ARENAVIRUS; BIOTERRORISM; BUNYAVIRIDAE; DRUG RESISTANCE, VIRAL; FILOVIRIDAE; HEMORRHAGIC FEVERS, VIRAL; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; SMALLPOX;

EID: 79951929147     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.547852     Document Type: Review

References (126)

1. Taubenberger JK, Morens DM. Influenza: the once and future pandemic. Public Health Rep 2010;125(Suppl 3):16-26.
2. De Clercq E. Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 2006;5(12):1015-25. (Pubitemid 44835128)
3. Davies WL, Grunert RR, Haff RF, et al. Antiviral activity of 1-adamantanamine (Amantadine). Science 1964;144:862-3.
4. Nakai K, Takeda K, Kimura H, et al. Obstructive acute renal failure related to amantadine intoxication. Am J Emerg Med 2009;27(3):371e5-371e7.
5. Smith JR. Oseltamivir in human avian influenza infection. J Antimicrob Chemother 2010;65(Suppl 2):ii25-33.
6. Tumpey TM, Garcia-Sastre A, Mikulasova A, et al. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci USA 2002;99(21):13849-54. (Pubitemid 35215469)
7. Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol 2008;41(1):13-9. (Pubitemid 350298978)
8. Yen HL, Herlocher LM, Hoffmann E, et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 2005;49(10):4075-84. (Pubitemid 41400949)
9. Hurt AC, Holien JK, Parker MW, Barr IG. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs 2009;69(18):2523-31.
10. Hauge SH, Dudman S, Borgen K, et al. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 2009;15(2):155-62.
11. Duwe S, Heider A, Braun C, et al. Person-to-person transmission of oseltamivir-resistant influenza A/ H1N1 viruses in two households; Germany 2007/08. J Clin Virol 2009;46(3):295-7.
12. Hurt AC, Lowther S, Middleton D, Barr IG. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. Antiviral Res 2010;87(3):361-6.
13. Williamson JC, Pegram PS. Neuraminidase inhibitors in patients with underlying airways disease. Am J Respir Med 2002;1(2):85-90. (Pubitemid 37038926)
14. Masuda T, Shibuya S, Arai M, et al. Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir. Bioorg Med Chem Lett 2003;13(4):669-73. (Pubitemid 36298465)
15. Castillo R, Holland LE, Boltz DA. Peramivir and its use in H1N1 influenza. Drug Today 2010;46(6):399-408.
16. Guo CT, Sun XL, Kanie O, et al. An O-glycoside of sialic acid derivative that inhibits both hemagglutinin and sialidase activities of influenza viruses. Glycobiology 2002;12(3):183-90. (Pubitemid 34567864)
17. Matrosovich M, Klenk HD. Natural and synthetic sialic acid-containing inhibitors of influenza virus receptor binding. Rev Med Virol 2003;13(2):85-97. (Pubitemid 36323672)
18. Landers JJ, Cao Z, Lee I, et al. Prevention of influenza pneumonitis by sialic Acid-conjugated dendritic polymers. J Infect Dis 2002;186(9):1222-30. (Pubitemid 35193000)
19. Totani K, Kubota T, Kuroda T, et al. Chemoenzymatic synthesis and application of glycopolymers containing multivalent sialyloligosaccharides with a poly(L-glutamic acid) backbone for inhibition of infection by influenza viruses. Glycobiology 2003;13(5):315-26. (Pubitemid 36592319)
20. Tsuchida A, Kobayashi K, Matsubara N, et al. Simple synthesis of sialyllactose-carrying polystyrene and its binding with influenza virus. Glycoconj J 1998;15(11):1047-54. (Pubitemid 29201842)
21. Matsubara T, Onishi A, Saito T, et al. Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy. J Med Chem 2010;53(11):4441-9.
22. Malakhov MP, Aschenbrenner LM, Smee DF, et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006;50(4):1470-9.
23. Ehrhardt C, Seyer R, Hrincius ER, et al. Interplay between influenza A virus and the innate immune signaling. Microbes Infect 2010;12(1):81-7.
24. Solorzano A, Webby RJ, Lager KM, et al. Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J Virol 2005;79(12):7535-43. (Pubitemid 40756789)
25. Basu D, Walkiewicz MP, Frieman M, et al. Novel influenza virus NS1 antagonists block replication and restore innate immune function. J Virol 2009;83(4):1881-91.
26. Smee DF, Hurst BL, Egawa H, et al. Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J Antimicrob Chemoth 2009;64(4):741-6.
27. Kiso M, Takahashi K, Sakai-Tagawa Y, et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA 2010;107(2):882-7.
28. Wunderlich K, Mayer D, Ranadheera C, et al. Identification of a PA-binding peptide with inhibitory activity against Influenza A and B virus replication. PLoS ONE 2009;4(10):e7517.
29. Zhang W, Wang CY, Yang ST, et al. Inhibition of highly pathogenic avian influenza virus H5N1 replication by the small interfering RNA targeting polymerase A gene. Biochem Biophys Res Commun 2009;390(3):421-6.
30. Mickleburgh I, Geng F, Tiley L. Mesoionic heterocyclic compounds as candidate messenger RNA cap analogue inhibitors of the influenza virus RNA polymerase cap-binding activity. Antivir Chem Chemother 2009;19(5):213-18.
31. Hastings JC, Selnick H, Wolanski B, Tomassini JE. Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors. Antimicrob Agents Chemother 1996;40(5):1304-7. (Pubitemid 26141399)
32. Sidwell RW, Bailey KW, Wong MH, et al. In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res 2005;68(1):10-17. (Pubitemid 41338577)
33. Nguyen JT, Hoopes JD, Le MH, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS ONE 2010;5(2):e9332.
34. Ludwig S. Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. J Antimicrob Chemother 2009;64(1):1-4.
35. Nimmerjahn F, Dudziak D, Dirmeier U, et al. Active NF-kappaB signalling is a prerequisite for influenza virus infection. J Gen Virol 2004;85(Pt 8):2347-56. (Pubitemid 39162607)
36. Kashyap AK, Steel J, Rubrum A, et al. Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries. PLoS Pathog 2010;6(7):e1000990.
37. Oh HL, Akerstrom S, Shen S, et al. An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses. J Virol 2010;84(16):8275-86.
38. De Clercq E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin Microbiol Rev 2001;14(2):382-97. (Pubitemid 32294676)
39. Sidwell RW, Allen LB, Khare GP, et al. Effect of 1-beta-D-ribofuranosyl1- 1,2,4- triazole-3-carboxamide (virazole, ICN 1229) on herpes and vaccinia keratitis and encephalitis in laboratory animals. Antimicrob Agents Chemother 1973;3(2):242-6.
40. De Clercq E, Cools M, Balzarini J, et al. Antiviral activities of 5-ethynyl-1-beta-Dribofuranosylimidazole- 4-carboxamide and related compounds. Antimicrob Agents Chemother 1991;35(4):679-84.
41. De Clercq E, Descamps J, De Somer P, Holy A. (S)-9-(2,3-Dihydroxypropyl) adenine: an aliphatic nucleoside analog with broad-spectrum antiviral activity. Science 1978;200(4341):UNKNOWN.
42. De Clercq E, Montgomery JA. Broad-spectrum antiviral activity of the carbocyclic analog of 3-deazaadenosine. Antiviral Res 1983;3(1):17-24. (Pubitemid 13105965)
43. Borchardt RT, Keller BT, Patel-Thombre U, Neplanocin A. A potent inhibitor of S-adenosylhomocysteine hydrolase and of vaccinia virus multiplication in mouse L929 cells. J Biol Chem 1984;259(7):4353-8. (Pubitemid 14127799)
44. De Clercq E. Antiviral and antitumor activities of 5-substituted 2¢-deoxyuridines. Methods Find Exp Clin Pharmacol 1980;2(5):253-67. (Pubitemid 11254698)
45. Hasobe M, McKee JG, Borcherding DR, Borchardt RT. 9-(trans-2¢,trans- 3¢-Dihydroxycyclopent- 4¢-enyl)-adenine and -3-deazaadenine: analogs of neplanocin A which retain potent antiviral activity but exhibit reduced cytotoxicity. Antimicrob Agents Chemother 1987;31(11):1849-51. (Pubitemid 17157657)
46. Smee DF. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother 2008;19(3):115-24.
47. De Clercq E. The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. Antiviral Res 2007;75(1):1-13. (Pubitemid 46610520)
48. Jesus DM, Costa LT, Goncalves DL, et al. Cidofovir inhibits genome encapsidation and affects morphogenesis during the replication of vaccinia virus. J Virol 2009;83(22):11477-90.
49. Buller RM, Owens G, Schriewer J, et al. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 2004;318(2):474-81. (Pubitemid 38224291)
50. Parker S, Siddiqui AM, Oberle C, et al. Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies. Virology 2009;385(1):11-21.
51. Quenelle DC, Keith KA, Kern ER. In vitro and in vivo evaluation of isatin-beta-thiosemicarbazone and marboran against vaccinia and cowpox virus infections. Antiviral Res 2006;71(1):24-30.
52. Charity JC, Katz E, Moss B. Amino acid substitutions at multiple sites within the vaccinia virus D13 scaffold protein confer resistance to rifampicin. Virology 2007;359(1):227-32. (Pubitemid 46215704)
53. Seiter K. Toxicity of the topoisomerase II inhibitors. Expert Opin Drug Saf 2005;4(2):219-34. (Pubitemid 40867335)
54. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106(4):1154-63. (Pubitemid 41130866)
55. Mike S, Harrison C, Coles B, et al. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev 2006;(4):CD005247.
56. Martinelli V, Radaelli M, Straffi L, et al. Mitoxantrone: benefits and risks in multiple sclerosis patients. Neurol Sci 2009;30(Suppl 2):S167-70.
57. Deng L, Dai P, Ciro A, et al. Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly. J Virol 2007;81(24):13392-402. (Pubitemid 350247836)
58. De Clercq E. Emerging antiviral drugs. Expert Opin Emerg Drugs 2008;13(3):393-416.
59. Bolken TC, Hruby DE. Tecovirimat for smallpox infections. Drugs Today (Barc) 2010;46(2):109-17.
60. Chen Y, Peng C, Sullivan C, et al. Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. Anticancer Agents Med Chem 2010;10(2):111-15.
61. Reeves PM, Bommarius B, Lebeis S, et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med 2005;11(7):731-9. (Pubitemid 41021205)
62. Pytel D, Sliwinski T, Poplawski T, et al. Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem 2009;9(1):66-76.
63. Yang HL, Kim SK, Kim M, et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest 2005;115(2):379-87. (Pubitemid 40385479)
64. Borio L, Inglesby T, Peters CJ, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002;287(18):2391-405. (Pubitemid 34493202)
65. Ascenzi P, Bocedi A, Heptonstall J, et al. Ebolavirus and marburgvirus: insight the filoviridae family. Mol Aspects Med 2008;29(3):151-85.
66. Geisbert TW, Bausch DG, Feldmann H. Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol 2010;20(6):344-57.
67. Barrientos LG, Gronenborn AM. The highly specific carbohydrate-binding protein cyanovirin-N: structure, anti-HIV/Ebola activity and possibilities for therapy. Mini Rev Med Chem 2005;5(1):21-31. (Pubitemid 40124840)
68. Barrientos LG, Lasala F, Otero JR, et al. In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins. J Infect Dis 2004;189(8):1440-3. (Pubitemid 38543593)
69. Barrientos LG, O'Keefe BR, Bray M, et al. Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. Antiviral Res 2003;58(1):47-56. (Pubitemid 36507221)
70. Lee JE, Saphire EO. Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. Curr Opin Struct Biol 2009;19(4):408-17.
71. Lee JE, Saphire EO. Ebolavirus glycoprotein structure and mechanism of entry. Future Virol 2009;4(6):621-35.
72. Hartlieb B, Modrof J, Muhlberger E, et al. Oligomerization of Ebola virus VP30 is essential for viral transcription and can be inhibited by a synthetic peptide. J Biol Chem 2003;278(43):41830-6. (Pubitemid 37310443)
73. Spurgers KB, Sharkey CM, Warfield KL, Bavari S. Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res 2008;78(1):26-36.
74. Warfield KL, Swenson DL, Olinger GG, et al. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog 2006;2(1):e1.
75. Enterlein S, Warfield KL, Swenson DL, et al. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother 2006;50(3):984-93. (Pubitemid 43327804)
76. Swenson DL, Warfield KL, Warren TK, et al. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother 2009;53(5):2089-99.
77. Warren TK, Warfield KL, Wells J, et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 2010;16(9):991-4.
78. Fowler T, Bamberg S, Moller P, et al. Inhibition of Marburg virus protein expression and viral release by RNA interference. J Gen Virol 2005;86(Pt 4):1181-8. (Pubitemid 40485676)
79. Groseth A, Hoenen T, Alimonti JB, et al. In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics. J Infect Dis 2007;196(Suppl 2):S382-9. (Pubitemid 351417285)
80. Bray M, Driscoll J, Huggins JW. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res 2000;45(2):135-47. (Pubitemid 30156782)
81. Huggins J, Zhang ZX, Bray M. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. J Infect Dis 1999;179(Suppl 1):S240-7. (Pubitemid 29091408)
82. Vittori S, Dal Ben D, Lambertucci C, et al. Antiviral properties of deazaadenine nucleoside derivatives. Curr Med Chem 2006;13(29):3529-52. (Pubitemid 44873745)
83. Bray M, Raymond JL, Geisbert T, Baker RO. 3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice. Antiviral Res 2002;55(1):151-9. (Pubitemid 34655650)
84. Warren TK, Warfield KL, Wells J, et al. Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrob Agents Chemother 2010;54(5):2152-9.
85. Kinch MS, Yunus AS, Lear C, et al. FGI-104: a broad-spectrum small molecule inhibitor of viral infection. Am J Transl Res 2009;1(1):87-98.
86. Aman MJ, Kinch MS, Warfield K, et al. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res 2009;83(3):245-51.
87. Spurgers KB, Alefantis T, Peyser BD, et al. Identification of essential filovirion-associated host factors by serial proteomic analysis and RNAi screen. Mol Cell Proteomics 2010;9(12):2690-703.
88. Charrel RN, De Lamballerie X. Arenaviruses other than Lassa virus. Antiviral Res 2003;57(1-2):89-100. (Pubitemid 36254723)
89. Briese T, Paweska JT, McMullan LK, et al. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog 2009;5(5):e1000455.
90. Delgado S, Erickson BR, Agudo R, et al. Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog 2008;4(4):e1000047.
91. McKee KT Jr, Oro JG, Kuehne AI, et al. Candid No. 1 Argentine hemorrhagic fever vaccine protects against lethal Junin virus challenge in rhesus macaques. Intervirology 1992;34(3):154-63. (Pubitemid 23108097)
92. Maiztegui JI, McKee KT Jr, Barrera Oro JG, et al. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J Infect Dis 1998;177(2):277-83. (Pubitemid 28063750)
93. Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat Med 2004;10(12 Suppl):S110-21. (Pubitemid 40018234)
94. McKee KT Jr, Huggins JW, Trahan CJ, Mahlandt BG. Ribavirin prophylaxis and therapy for experimental argentine hemorrhagic fever. Antimicrob Agents Chemother 1988;32(9):1304-9.
95. Perez M, Greenwald DL, De la Torre JC. Myristoylation of the RING finger Z protein is essential for arenavirus budding. J Virol 2004;78(20):11443-8. (Pubitemid 39299691)
96. Cordo SM, Candurra NA, Damonte EB. Myristic acid analogs are inhibitors of Junin virus replication. Microbes Infect 1999;1(8):609-14.
97. Strecker T, Maisa A, Daffis S, et al. The role of myristoylation in the membrane association of the Lassa virus matrix protein Z. Virol J 2006;3:93.
98. Garcia CC, Topisirovic I, Djavani M, et al. An antiviral disulfide compound blocks interaction between arenavirus Z protein and cellular promyelocytic leukemia protein. Biochem Biophys Res Commun 2010;393(4):625-30.
99. Garcia CC, Ellenberg PC, Artuso MC, et al. Characterization of Junin virus particles inactivated by a zinc finger-reactive compound. Virus Res 2009;143(1):106-13.
100. Garcia CC, Djavani M, Topisirovic I, et al. Arenavirus Z protein as an antiviral target: virus inactivation and protein oligomerization by zinc finger-reactive compounds. J Gen Virol 2006;87(Pt 5):1217-28.
101. Sepulveda CS, Garcia CC, Damonte EB. Inhibition of arenavirus infection by thiuram and aromatic disulfides. Antiviral Res 2010;87(3):329-37.
102. Artuso MC, Ellenberg PC, Scolaro LA, et al. Inhibition of Junin virus replication by small interfering RNAs. Antiviral Res 2009;84(1):31-7.
103. Bolken TC, Laquerre S, Zhang Y, et al. Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res 2006;69(2):86-97. (Pubitemid 43152044)
104. York J, Dai D, Amberg SM, Nunberg JH. pH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors. J Virol 2008;82(21):10932-9. (Pubitemid 352691170)
105. Larson RA, Dai D, Hosack VT, et al. Identification of a broad-spectrum arenavirus entry inhibitor. J Virol 2008;82(21):10768-75. (Pubitemid 352691167)
106. Gowen BB, Wong MH, Jung KH, et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 2007;51(9):3168-76. (Pubitemid 350067524)
107. Gowen BB, Smee DF, Wong MH, et al. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS ONE 2008;3(11):e3725.
108. Rojek JM, Pasqual G, Sanchez AB, et al. Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses. J Virol 2010;84(1):573-84.
109. Ji WT, Liu HJ. PI3K-Akt signaling and viral infection. Recent Pat Biotechnol 2008;2(3):218-26.
110. Linero FN, Scolaro LA. Participation of the phosphatidylinositol 3-kinase/Akt pathway in Junin virus replication in vitro. Virus Res 2009;145(1):166-70.
111. Vela EM, Bowick GC, Herzog NK, Aronson JF. Genistein treatment of cells inhibits arenavirus infection. Antiviral Res 2008;77(2):153-6.
112. Ergonul O. Treatment of Crimean-Congo hemorrhagic fever. Antiviral Res 2008;78(1):125-31.
113. Koksal I, Yilmaz G, Aksoy F, et al. The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey. J Clin Virol 2010;47(1):65-8.
114. Pittman PR, Liu CT, Cannon TL, et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine 1999;18(1-2):181-9. (Pubitemid 29432151)
115. Niklasson B, Peters CJ, Bengtsson E, Norrby E. Rift Valley fever virus vaccine trial: study of neutralizing antibody response in humans. Vaccine 1985;3(2):123-7. (Pubitemid 15026714)
116. Ikegami T, Makino S. Rift valley fever vaccines. Vaccine 2009;27(Suppl 4):D69-72.
117. Wolf MC, Freiberg AN, Zhang T, et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci USA 2010;107(7):3157-62.
118. Bouloy M, Weber F. Molecular biology of rift valley Fever virus. Open Virol J 2010;4:8-14.
119. Gowen BB, Wong MH, Jung KH, et al. Prophylactic and therapeutic intervention of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with interferon alfacon-1. Antiviral Res 2008;77(3):215-24.
120. Gowen BB, Wong MH, Jung KH, et al. Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. Antiviral Res 2010;86(2):121-7.
121. Muranyi W, Bahr U, Zeier M, van der Woude FJ. Hantavirus infection. J Am Soc Nephrol 2005;16(12):3669-79. (Pubitemid 46211288)
122. Gavrilovskaya IN, Shepley M, Shaw R, et al. Beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci USA 1998;95(12):7074-9. (Pubitemid 28278109)
123. Larson RS, Brown DC, Ye C, Hjelle B. Peptide antagonists that inhibit Sin Nombre virus and hantaan virus entry through the beta3-integrin receptor. J Virol 2005;79(12):7319-26. (Pubitemid 40756767)
124. Hall PR, Malone L, Sillerud LO, et al. Characterization and NMR solution structure of a novel cyclic pentapeptide inhibitor of pathogenic hantaviruses. Chem Biol Drug Des 2007;69(3):180-90. (Pubitemid 46608456)
125. Xu R, Yang XY, Yang DF, et al. Phase I evaluation of the safety and pharmacokinetics of a single-dose intravenous injection of a murine monoclonal antibody against Hantaan virus in healthy volunteers. Antimicrob Agents Chemother 2009;53(12):5055-9.
126. Yang J, Chen R, Wei J, et al. Production and characterization of a recombinant single-chain antibody against Hantaan virus envelop glycoprotein. Appl Microbiol Biotechnol 2010;86(4):1067-75